Knee cartilage damage affects nearly half a million Americans each year due to long-term wear and tear and everyday accidents. For decades, many treatments have focused on managing pain and restoring function rather than replacing damaged cartilage with healthy tissue. Regentis Biomaterials Ltd. (NYSE American: RGNT) is pursuing a different approach with GelrinC, an off-the-shelf hydrogel implant designed to support the regeneration of cartilage within the damaged area.
Cartilage is notoriously difficult for the body to repair on its own because it has limited blood supply. This can make significant injuries difficult to heal and leave patients vulnerable to persistent pain, stiffness, and progressive joint degeneration. Researchers across the field, including teams at Duke University and the Mayo Clinic, are increasingly focused on restoring damaged cartilage rather than simply managing symptoms.
GelrinC is designed to support the body’s natural cartilage-regeneration process through a gradual, controlled repair environment. Early clinical data has provided encouraging evidence for GelrinC, which already has approval in Europe. An FDA-authorized pivotal trial is now advancing its development toward potential U.S. approval.
The implications of this announcement are significant for patients and the orthopedic industry. If GelrinC gains U.S. approval, it could offer a new treatment option that goes beyond symptom management to potentially restore damaged knee cartilage. This could reduce the need for more invasive procedures and improve long-term outcomes for individuals suffering from cartilage defects.
“Researchers across the field, from Duke University to Mayo Clinic, are increasingly focused on restoring damaged cartilage rather than simply managing the symptoms associated with its loss,” the company noted in its press release. Regentis Biomaterials is positioning GelrinC as a potential new standard of care.
The latest news and updates relating to RGNT are available in the company’s newsroom at ibn.fm/RGNT. This content was disseminated on behalf of (NYSE American: RGNT) as part of a paid marketing engagement with IBN. For full terms of use and disclaimers, please see https://www.BioMedWire.com/Disclaimer.
InvestorWire, a specialized communications platform, provides wire-grade press release syndication and corporate communications solutions. For more information, visit https://www.InvestorWire.com. The full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
